Friedman Billings Downgrades Acorda Therapeutics (ACOR) to Market Perform
More News related to ACOR
- Acorda Therapeutics to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
- Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer
- Acorda Therapeutics to Present at the 2008 Deutsche Bank Biotech Boston Confab
- Acorda Therapeutics (ACOR) Misses Q3 EPS View By 5c
- Acorda Therapeutics Reports Third Quarter 2008 Financial Results
More News related to Downgrades
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Friedman Billings downgrades Acorda Therapeutics (Nasdaq: ACOR) from Outperform to Market Perform, citing current valuation. However, the firm says the company may build a larger sale force or be the target of a takeover depending on an upcoming FDA decision. Price target $32.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage, biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS).
Related Categories
DowngradesStocks Mentioned
+0.67Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
